open access

Vol 6, No 3 (2017)
REVIEW ARTICLES
Published online: 2017-09-29
Get Citation

New technologies and metabolic control in type 1 diabetes mellitus

Mateusz Klamann, Lilianna Majkowska
DOI: 10.5603/DK.2017.0018
·
Pubmed: 7493286
·
Clinical Diabetology 2017;6(3):111-114.

open access

Vol 6, No 3 (2017)
REVIEW ARTICLES
Published online: 2017-09-29

Abstract

The introduction of more rigorous criteria of metabolic control, rapid- and long-acting insulin analogues and the advances in diabetes technology (improved insulin deliv­ery systems and blood glucose monitoring) have not been translated into better glycaemic control in patients with type 1 diabetes, which is quite similar to that observed 20–30 years ago in the Diabetes Control and Complica­tions Trial (DCCT). Continuous subcutaneous insulin infusion (CSII) provided by personal insulin pumps may improve glycaemic control; however, observed results are not so good as it has been expected and are only slightly better or similar to these obtained with multiple daily insulin injections (MDII). Real-time continuous glucose monitoring (CGM) seems to be very useful to achieve target glycaemic control and to avoid hypoglycaemia in both CSII and MDII patients. While using CGM, levels of HbA1c are lower, time spent in hypoglycaemia is shorter and frequency of hypoglycaemia episodes is reduced. To receive optimum benefit, excellent compliance and fre­quent readings of measurements are required. The most common real-time sensors used in Poland are: Medtronic Enlite, Dexcom G4 Platinum and Abbott FreeStyle Libre. Unfortunately, for majority of patients with type 1 diabe­tes CGM devices have no reimbursement. (Clin Diabetol 2017; 6, 3: 111–114)

Abstract

The introduction of more rigorous criteria of metabolic control, rapid- and long-acting insulin analogues and the advances in diabetes technology (improved insulin deliv­ery systems and blood glucose monitoring) have not been translated into better glycaemic control in patients with type 1 diabetes, which is quite similar to that observed 20–30 years ago in the Diabetes Control and Complica­tions Trial (DCCT). Continuous subcutaneous insulin infusion (CSII) provided by personal insulin pumps may improve glycaemic control; however, observed results are not so good as it has been expected and are only slightly better or similar to these obtained with multiple daily insulin injections (MDII). Real-time continuous glucose monitoring (CGM) seems to be very useful to achieve target glycaemic control and to avoid hypoglycaemia in both CSII and MDII patients. While using CGM, levels of HbA1c are lower, time spent in hypoglycaemia is shorter and frequency of hypoglycaemia episodes is reduced. To receive optimum benefit, excellent compliance and fre­quent readings of measurements are required. The most common real-time sensors used in Poland are: Medtronic Enlite, Dexcom G4 Platinum and Abbott FreeStyle Libre. Unfortunately, for majority of patients with type 1 diabe­tes CGM devices have no reimbursement. (Clin Diabetol 2017; 6, 3: 111–114)

Get Citation

Keywords

type 1 diabetes; metabolic control, continuous glucose monitoring; advanced technologies

About this article
Title

New technologies and metabolic control in type 1 diabetes mellitus

Journal

Clinical Diabetology

Issue

Vol 6, No 3 (2017)

Pages

111-114

Published online

2017-09-29

DOI

10.5603/DK.2017.0018

Pubmed

7493286

Bibliographic record

Clinical Diabetology 2017;6(3):111-114.

Keywords

type 1 diabetes
metabolic control
continuous glucose monitoring
advanced technologies

Authors

Mateusz Klamann
Lilianna Majkowska

References (21)
  1. Polskie Towarzystwo ogiczne (PTD): Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2017. Stanowisko Polskiego Towarzystwa ogicznego. Diabetol. Klin. 2017; 3(Suppl. A): A1–A81.
  2. American Diabetes Association. Standards of Medical Care in Diabetes—2017 . Diabetes Care 2017;40(Suppl. 1):S1–S135. Diabetes Care. 2017; 40(1): S1–S132.
  3. Miller KM, Foster NC, Beck RW, et al. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry. Diabetes Care. 2015; 38(6): 971–978.
  4. Gerstl EM, Rabl W, Rosenbauer J, et al. Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr. 2008; 167(4): 447–453.
  5. The Diabetes Control and Complications Trial Research Group: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Eng. J. Med. 1993; 329(14): 977–986.
  6. Nathan DM, Cleary PA, Backlund JY JY, et al. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Engl. J. Med. 2005; 353: 2643–2653.
  7. Foster NC, Miller KM, Tamborlane WV, et al. Continuous Glucose Monitoring in Patients With Type 1 Diabetes Using Insulin Injections. Diabetes Care. 2016; 39(6): e81–e82.
  8. Golden SH, Brown T, Yeh HC, et al. Methods for insulin delivery and glucose monitoring: Comparative effectiveness. Review No. 57. (prepared by Johns Hopkins University Evidence-based Practise Center under contract No. 290-2007-10061-I). AHRQ Publication No. 12-EHC036-EF. Rockville. Agency for Healthcare Research and Quality. 2012.
  9. DeVries JH, Snoek FJ, Kostense PJ, et al. A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic Control. Diabetes Care. 2002; 25(11): 2074–2080.
  10. Misso M, Egberts K, Page M, et al. Cochrane review: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Evidence-Based Child Health: A Cochrane Review Journal. 2010; 5(4): 1726–1867.
  11. REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ. 2017; 356: j1285.
  12. Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016; 18(9): 532–538.
  13. Wojciechowski P, Ryś P, Lipowska A, et al. Efficacy and safety comparison of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes: systematic review and meta-analysis. Pol Arch Med Wewn. 2011; 121(10): 333–343.
  14. Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017; 317(4): 379–387.
  15. Beck RW, Riddlesworth T, Ruedy K, et al. DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017; 317(4): 371–378.
  16. Bolinder J, Weltgasser R, Antuna R, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016; 388(10057): 2254–2263.
  17. Ruiz-de-Adana M, Dominguez-Lopez ME, Gonzalez-Molero I, et al. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study. Med. Clin. 2016; 146(6): 239–246.
  18. Battelino T, Phillip M, Bratina N, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011; 34(4): 795–800.
  19. van Beers C, DeVries J, Kleijer S, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016; 4(11): 893–902.
  20. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group J J, Beck RW, Hirsch IB. The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care. 2009; 32(8): 1378–1383.
  21. Facchinetti A. Continuous Glucose Monitoring Sensors: Past, Present and Future Algorithmic Challenges. Sensors (Basel). 2016; 16(12): 2093.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl